| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 605 |
| 1 | IPILIMUMAB | 217 |
| 2 | PEMBROLIZUMAB | 153 |
| 3 | CARBOPLATIN | 66 |
| 4 | OXALIPLATIN | 63 |
| 5 | ATEZOLIZUMAB | 62 |
| 6 | PACLITAXEL | 60 |
| 7 | PACLITAXEL (AIBUMIN-BOUND) | 52 |
| 8 | AMLODIPINE | 40 |
| 9 | BEVACIZUMAB | 39 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ADENINE | 2 | 0.0408 |
| 1 | LULICONAZOLE | 2 | 0.0114 |
| 2 | NIVOLUMAB | 605 | 0.0062 |
| 3 | VALERIAN ROOT, PASSIFLORA, MAGNESIUM CARBONATE | 1 | 0.0054 |
| 4 | IPILIMUMAB | 217 | 0.0049 |
| 5 | TREMELIMUMAB | 19 | 0.0043 |
| 6 | NALDEMEDINE | 6 | 0.0036 |
| 7 | BETHANECHOL CHLORIDE | 2 | 0.0036 |
| 8 | VONOPRAZAN FUMARATE | 23 | 0.0028 |
| 9 | AZILSARTAN KAMEDOXOMIL | 7 | 0.0023 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 812 | 0.0082 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 236 | 0.0049 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 14 | 0.0022 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 38 | 0.0018 |
| 4 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 7 | 0.0008 |
| 5 | Chloride Channel Activator [EPC] | 7 | 0.0007 |
| 6 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 7 | Platinum-based Drug [EPC] | 142 | 0.0005 |
| 8 | Antihypoglycemic Agent [EPC] | 2 | 0.0005 |
| 9 | Microtubule Inhibitor [EPC] | 64 | 0.0004 |